Literature DB >> 34435232

Long-term expression changes of immune-related genes in prostate cancer after radiotherapy.

Iris Eke1,2, Molykutty J Aryankalayil3, Michelle A Bylicky3, Veit Sandfort4, Claire Vanpouille-Box5, Saravanan Nandagopal6, Edward E Graves6, Amato J Giaccia6,7, C Norman Coleman3,8.   

Abstract

The expression of immune-related genes in cancer cells can alter the anti-tumor immune response and thereby impact patient outcomes. Radiotherapy has been shown to modulate immune-related genes dependent on the fractionation regimen. To identify long-term changes in gene expression after irradiation, PC3 (p53 deleted) and LNCaP (p53 wildtype) prostate cancer cells were irradiated with either a single dose (SD, 10 Gy) or a fractionated regimen (MF) of 10 fractions (1 Gy per fraction). Whole human genome arrays were used to determine gene expression at 24 h and 2 months after irradiation. Immune pathway activation was analyzed with Ingenuity Pathway Analysis software. Additionally, 3D colony formation assays and T-cell cytotoxicity assays were performed. LNCaP had a higher basal expression of immunogenic genes and was more efficiently killed by cytotoxic T-cells compared to PC3. In both cell lines, MF irradiation resulted in an increase in multiple immune-related genes immediately after irradiation, while at 2 months, SD irradiation had a more pronounced effect on radiation-induced gene expression. Both immunogenic and immunosuppressive genes were upregulated in the long term in PC3 cells by a 10 Gy SD irradiation but not in LNCaP. T-cell-mediated cytotoxicity was significantly increased in 10 Gy SD PC3 cells compared to the unirradiated control and could be further enhanced by treatment with immune checkpoint inhibitors. Irradiation impacts the expression of immune-related genes in cancer cells in a fractionation-dependent manner. Understanding and targeting these changes may be a promising strategy for primary prostate cancer and recurrent tumors.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  Checkpoint inhibitor; Immune modulation; Immune therapy; Long-term effect; Prostate cancer; Radiation therapy

Mesh:

Year:  2021        PMID: 34435232      PMCID: PMC8873240          DOI: 10.1007/s00262-021-03036-w

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  48 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

Review 2.  Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling.

Authors:  Andy J Minn; E John Wherry
Journal:  Cell       Date:  2016-04-07       Impact factor: 41.582

3.  Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes.

Authors:  Charlie T Garnett; Claudia Palena; Mala Chakraborty; Mala Chakarborty; Kwong-Yok Tsang; Jeffrey Schlom; James W Hodge
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

Review 4.  Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer.

Authors:  Nicholas G Zaorsky; Talha Shaikh; Colin T Murphy; Mark A Hallman; Shelly B Hayes; Mark L Sobczak; Eric M Horwitz
Journal:  Cancer Treat Rev       Date:  2016-06-17       Impact factor: 12.111

5.  Repression of the minimal HLA-B promoter by c-myc and p53 occurs through independent mechanisms.

Authors:  M Griffioen; W T Steegenga; I J Ouwerkerk; L T Peltenburg; A G Jochemsen; P I Schrier
Journal:  Mol Immunol       Date:  1998-09       Impact factor: 4.407

6.  Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells.

Authors:  Craig Gedye; Juliet Quirk; Judy Browning; Suzanne Svobodová; Thomas John; Pavel Sluka; P Rod Dunbar; Denis Corbeil; Jonathan Cebon; Ian D Davis
Journal:  Cancer Immunol Immunother       Date:  2009-02-17       Impact factor: 6.968

7.  Long-term Tumor Adaptation after Radiotherapy: Therapeutic Implications for Targeting Integrins in Prostate Cancer.

Authors:  Iris Eke; Adeola Y Makinde; Molykutty J Aryankalayil; Jessica L Reedy; Deborah E Citrin; Sunita Chopra; Mansoor M Ahmed; C Norman Coleman
Journal:  Mol Cancer Res       Date:  2018-07-24       Impact factor: 5.852

8.  High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot.

Authors:  Simon P Keam; Heloise Halse; Thu Nguyen; Minyu Wang; Nicolas Van Kooten Losio; Catherine Mitchell; Franco Caramia; David J Byrne; Sue Haupt; Georgina Ryland; Phillip K Darcy; Shahneen Sandhu; Piers Blombery; Ygal Haupt; Scott G Williams; Paul J Neeson
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

9.  Radiotherapy induces responses of lung cancer to CTLA-4 blockade.

Authors:  Silvia C Formenti; Nils-Petter Rudqvist; Encouse Golden; Benjamin Cooper; Erik Wennerberg; Claire Lhuillier; Claire Vanpouille-Box; Kent Friedman; Lucas Ferrari de Andrade; Kai W Wucherpfennig; Adriana Heguy; Naoko Imai; Sacha Gnjatic; Ryan O Emerson; Xi Kathy Zhou; Tuo Zhang; Abraham Chachoua; Sandra Demaria
Journal:  Nat Med       Date:  2018-11-05       Impact factor: 53.440

Review 10.  Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer.

Authors:  David Lorente; Karim Fizazi; Christopher Sweeney; Johann S de Bono
Journal:  Eur Urol Focus       Date:  2016-11-23
View more
  1 in total

1.  Radiotherapy alters expression of molecular targets in prostate cancer in a fractionation- and time-dependent manner.

Authors:  Iris Eke; Molykutty J Aryankalayil; Michelle A Bylicky; Adeola Y Makinde; Lance Liotta; Valerie Calvert; Emanuel F Petricoin; Edward E Graves; C Norman Coleman
Journal:  Sci Rep       Date:  2022-03-03       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.